The FBXO38 Knockout Raji Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout cell population generated by disrupting the FBXO38 gene in the human Raji B lymphocyte cell line. This heterogeneous pool of edited cells enables loss-of-function investigations without the bias of single-cell cloning. The product is designed for researchers studying FBXO38-dependent ubiquitin pathways in a polyclonal context, preserving natural genetic variation.
The host Raji cell line is an Epstein-Barr virus (EBV)-positive Burkitt’s lymphoma B lymphocyte model extensively used in immunology and cancer research.
Raji cells display key B cell characteristics, including surface immunoglobulin expression, major histocompatibility complex (MHC)-mediated antigen presentation, and participation in humoral immunity. Their lymphoma origin provides a relevant background for exploring oncogenic mechanisms and immune checkpoint regulation.
FBXO38 serves as the substrate recognition subunit of the SKP1-CUL1-F-box protein (SCF) E3 ubiquitin ligase complex, which also comprises SKP1, CUL1, and RBX1. This complex catalyzes the transfer of ubiquitin to specific substrate proteins, targeting them for 26S proteasome-mediated degradation.
Among its targets, FBXO38 regulates the stability of programmed cell death protein 1 (PD-1), a critical immune checkpoint receptor. Through PD-1 ubiquitination, FBXO38 modulates immune receptor expression and signaling output. Upstream regulation of FBXO38 is achieved through transcriptional control and post-translational modifications, though the full landscape remains to be elucidated.
In the context of Raji B lymphocytes, loss of FBXO38 function is predicted to impair normal substrate degradation, leading to accumulation of proteins such as PD-1.
This dysregulation may alter immune checkpoint signaling, cell cycle progression, and apoptotic responses. Given Raji’s Burkitt’s lymphoma derivation, this knockout model offers a valuable tool to investigate how defects in the ubiquitin-proteasome system contribute to lymphoma pathogenesis and immune evasion strategies. It also facilitates studies on the interplay between protein homeostasis and B cell function.
Typical applications for these polyclonal knockout cells encompass the dissection of ubiquitin-mediated proteolysis in B lymphocytes, functional interrogation of FBXO38 in lymphoma, and substrate discovery through co-immunoprecipitation coupled with mass spectrometry.
Additional uses include analyzing SCF complex dynamics and modeling distal hereditary motor neuronopathy. Common experimental assays include Western blotting, RT-qPCR, flow cytometry, ubiquitination assays, and cell proliferation or apoptosis measurements. For technical details or ordering, please contact Ascent Research.
